Section Arrow
HOWL.NASDAQ
- Werewolf Therapeutics
Quotes are at least 15-min delayed:2024/10/31 19:41 EDT
Last
 2.555
-0.135 (-5.02%)
Day High 
2.75 
Prev. Close
2.69 
1-M High
4.18 
Volume 
566.64K 
Bid
2.51
Ask
2.54
Day Low
2.55 
Open
2.71 
1-M Low
1.81 
Market Cap 
117.56M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.84 
20-SMA 2.4 
50-SMA 2.27 
52-W High 8.1939 
52-W Low 1.66 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.38/-1.03
Enterprise Value
161.21M
Balance Sheet
Book Value Per Share
2.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
19.94M
Operating Revenue Per Share
0.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.